Literature DB >> 25883429

Alloimmunization to Red Cells and the Association of Alloantibodies Formation with Splenectomy Among Transfusion-Dependent β-Thalassemia Major/HbE Patients.

Suteenee Jansuwan1, Orathai Tangvarasittichai2, Surapon Tangvarasittichai3.   

Abstract

Severe hemolytic anemia in β-thalassemia major and β-thalassemias/HbE (β-TM) patients requires giving blood transfusions. Chronic blood transfusions lead to iron overload consequence with organs damage and risk of alloantibody-formation. This study evaluates the prevalence of red cell alloimmunization and estimates the risk of alloantibody-formation in chronic transfusion-dependent β-TM patients. This cross sectional study was conducted on 143 β-TM patients receiving regular transfusions. We tried to determine the frequency, types and factors influencing red cell alloimmunization in these transfusion-dependent β-TM patients. Median age of 25 (17.5 %) alloantibody-formation β-TM patients was 19.0 years (inter quartile 15.5-24.0 years). The alloantibodies were Anti-Rh (E) (13.1 %), Anti-Rh (D) (0.7 %). Thirty-four patients (23.8 %) of the sample had splenectomies of which 10 (29.4 %) had alloantibody-formation. The interval from first transfusion to antibody development varied from 1.5 to 14 years. Alloantibody-formation correlated with splenectomy and splenectomy correlated with number of transfusion (p < 0.005). In multiple logistic regression used to estimate the risk of alloantibodies formation with splenectomy; OR and 95 % CI were 2.88 (1.07-7.80), p = 0.037 after adjusting for other co-variates. The rate of red cell alloimmunization was 17.5 % and splenectomy associated with increased alloantibody-formation in these transfusion-dependent β-TM patients.

Entities:  

Keywords:  Alloantibody; Alloimmunization; Splenectomy; Transfusion; β-Thalassemia

Year:  2014        PMID: 25883429      PMCID: PMC4393396          DOI: 10.1007/s12291-014-0424-6

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  26 in total

1.  Suppressive effect of ferritin on in vitro lymphocyte function.

Authors:  Y Matzner; C Hershko; A Polliack; A M Konijn; G Izak
Journal:  Br J Haematol       Date:  1979-07       Impact factor: 6.998

2.  Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan.

Authors:  L-Y Wang; D-C Liang; H-C Liu; F-C Chang; C-L Wang; Y-S Chan; M Lin
Journal:  Transfus Med       Date:  2006-06       Impact factor: 2.019

3.  Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state.

Authors:  Sylvia T Singer; Frans A Kuypers; Lori Styles; Elliott P Vichinsky; Drucella Foote; Howard Rosenfeld
Journal:  Am J Hematol       Date:  2006-09       Impact factor: 10.047

4.  Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for iron-binding proteins in the control of lymphoid cell migration.

Authors:  M de Sousa; A Smithyman; C Tan
Journal:  Am J Pathol       Date:  1978-02       Impact factor: 4.307

5.  Serum-immunoglobulin levels in thalassaemia and the effects of splenectomy.

Authors:  C Wasi; P Wasi; P Thongcharoen
Journal:  Lancet       Date:  1971-07-31       Impact factor: 79.321

6.  Lymphoid cell sets and serum immunoglobulins in patients with thalassaemia intermedia: relationship to serum iron and splenectomy.

Authors:  A Kapadia; M de Sousa; A L Markenson; D R Miller; R A Good; S Gupta
Journal:  Br J Haematol       Date:  1980-07       Impact factor: 6.998

7.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  1999-07       Impact factor: 3.157

8.  Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.

Authors:  Alexis A Thompson; Melody J Cunningham; Sylvia T Singer; Ellis J Neufeld; Elliott Vichinsky; Robert Yamashita; Patricia Giardina; Hae-Young Kim; Felicia Trachtenberg; Janet L Kwiatkowski
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

9.  Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures?

Authors:  Henk Schonewille; Leo M G van de Watering; Anneke Brand
Journal:  Transfusion       Date:  2006-04       Impact factor: 3.157

10.  RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients.

Authors:  Reem Ameen; Salem Al-Shemmari; Salah Al-Humood; Rafiq I Chowdhury; Ohood Al-Eyaadi; Abdulaziz Al-Bashir
Journal:  Transfusion       Date:  2003-11       Impact factor: 3.157

View more
  2 in total

1.  Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review.

Authors:  Massimo Franchini; Gian Luca Forni; Giuseppe Marano; Mario Cruciani; Carlo Mengoli; Valeria Pinto; Lucia De Franceschi; Donatella Venturelli; Maddalena Casale; Martina Amerini; Martina Capuzzo; Giuliano Grazzini; Francesca Masiello; Ilaria Pati; Eva Veropalumbo; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

2.  Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb
Journal:  Asian J Transfus Sci       Date:  2017 Jan-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.